Lung cancer is the primary cause of mortality in the United States and around the globe.
Therapeutic options for lung cancer treatment include surgery, radiation therapy …

Cancers are highly complex diseases that are characterized by not only the overgrowth of
malignant cells but also an altered immune response. The inhibition and reprogramming of …

Chimeric antigen receptor (CAR) T cells have been approved for use in patients with B cell
malignancies or relapsed and/or refractory multiple myeloma, yet efficacy against most solid …

Lung cancer accounts for a relatively high proportion of malignant tumors. As the most
prevalent type of lung cancer, non-small cell lung cancer (NSCLC) is characterized by high …

Immune evasion contributes to cancer growth and progression. Cancer cells have the ability
to activate different immune checkpoint pathways that harbor immunosuppressive functions …

The development of neoplasia involves a complex and continuous interplay between
malignantly transformed cells and the tumour microenvironment (TME). Cancer …

Immune checkpoint blockade (ICB) has revolutionized cancer treatment. However,
resistance to ICB occurs frequently due to tumor-intrinsic alterations or extrinsic factors in the …

A proportion of patients with lung cancer experience long-term clinical benefit with immune
checkpoint inhibitors (ICIs). However, most patients develop disease progression during …

The T cell receptor (TCR) complex is a naturally occurring antigen sensor that detects,
amplifies and coordinates cellular immune responses to epitopes derived from cell surface …

Recent advances in neoantigen research have accelerated the development and regulatory
approval of tumor immunotherapies, including cancer vaccines, adoptive cell therapy and …